A COVID-19 call to action in Clinical Pharmacology & Therapeutics from Richard Peck, Daniel Weiner, Jack Cook and Bob Powell. “The Global Heads of Clinical Pharmacology from the pharmaceutic...
Commentary
Commentary on CTS: Time for the global pharmacology community to step up
In this commentary in Clinical and Translational Science, the authors urge the global translational and quantitative pharmacology community to come together and contribute our tools and know-how to fi...
COVID-19 drug development in the critically ill – a “special population”
Commentary by Carl Kirkpatrick, PhD. Professor at Monash University As the number of patients diagnosed with COVID-19 exceeded the 2.5 million worldwide, the impact on the hospital systems in many cou...
Ivermectin is unlikely to be clinically effective for COVID-19.
Commentary by Dr. Craig Rayner and Dr. Karen Yeo Recently in Antiviral research, Caly et al.(1) reported the in vitro activity of ivermectin against SARS-CoV-2 in SERO cells. The study, described th...
Pregnancy and COVID-19
Commentary by Mark Milad, PharmD Introduction According to the CDC, pregnant women seem to have the same risks from COVID-19 as adults who are not pregnant.1 However, pregnant women and newborns are...
COVID-19 drug development in the elderly – a “special population”
Commentary by Tom Polasek, MD, PhD, Director of Clinical Pharmacology, Certara The high morbidity and mortality rates of COVID-19 infection in the elderly highlight the importance of clinical pharmaco...
Optimizing clinical trial design with in silico simulation
by Dr. Keith Nieforth, Senior Director PMX-SW, Certara With the continued advancement of the COVID-19 pandemic, researchers all over the globe are dedicated to finding safe and effective treatments. W...
Drug Development in Times of the COVID-19 Pandemic
By Andreas Wallnöfer, General Partner of Biomed Partners VC, Executive Advisor to Certara, and former Head of Clinical Research & Exploratory Development at F. Hoffmann-La Roche. Even when we can...
Optimizing COVID‐19 candidate therapeutics: Thinking Without Borders
This commentary in Clinical and Translational Science by Drs. Craig R. Rayner, Patrick F. Smith, Kevin Hershberger, and David Wesche shares insights from past experiences with H5N1 and pH1N1 outbreaks...